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418 SECTION IV 
IMPAIRED STIMULATION OF A N F IN PATIENTS WITH 
CIRRHOSIS AND ASCITES 
A. L . Gerbes, R. M. Arendt, S. Silz, R. Liebermeister, T. Sauerbruch, 
and G . Paumgartner 
Departments of Medicine II and I, Klinikum Großhadern, University of Munich, 
D-8000 Munich, Federal Republic of Germany 
The pathophysiology of renal sodium retention and ascites formation in patients with 
cirrhosis of the liver has become rather perplexing. There is increasing evidence that activation 
of the renin-aldosterone system is just one of several factors involved in the impaired 
volume regulation of cirrhosis. For many years, a deficiency of a putative natriuretic hormone 
in cirrhosis has been postulated but never satisfactorily demonstrated. Therefore, investiga-
tions of the role of atrial natriuretic factor (ANF) in cirrhosis have been eagerly awaited. 
The first communication on ANF plasma levels in cirrhosis showed that there is no 
absolute deficiency of this novel natriuretic and diuretic hormone in patients with cirrhosis 
(1). These findings have been confirmed by several groups, reporting ANF plasma levels 
in patients with cirrhosis and ascites equal to or higher than normal (2). 
However, the immunoreactive ANF in plasma of patients with cirrhosis might comprise 
different molecular species with altered biological activity, as has been suggested in patients 
with congestive heart failure (3). By high performance gel permeation chromatography 
only negligible amounts of immunoreactivity coeluting with precursor forms of ANF 99-
126 have been detected (4). Thus, no evidence for major abnormalities of processing of 
ANF was found in cirrhosis. 
Neither basal plasma levels nor characterization of immunoreactivity necessarily reflect 
the functional status or the compensatory reactivity of the ANF system. Therefore, in the 
present study responsiveness of the ANF system to volume stimulation was investigated. 
Head-out water immersion (WI) into a thermoneutral bath has been shown to induce central 
hypervolemia with atrial distension and to prompt natriuresis and diuresis (5). Epstein and 
others have demonstrated in numerous investigations that WI is a useful tool for the study 
of volume regulation (6): it increases central volume by shifting blood from peripheral 
vessels thus obviating the necessity of infusing volume expanders that might alter plasma 
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composition. We demonstrated that W I rapidly increases ANF plasma levels in healthy 
human subjects (7). In the present study W I was used to investigate the response of ANF 
to acute volume stimulation in patients with cirrhosis. 
PATIENTS AND METHODS 
Twenty-five healthy controls and 21 patients with cirrhosis, 10 with and 11 without 
ascites, were investigated after informed consent had been obtained. There was no evidence 
for cardiovascular, renal, or pulmonary disease in controls or patients. No diuretics had 
been given to any subject for 1 week preceding the study. Subjects were on a hospital 
diet containing approximately 150 mEq sodium/day and were prohibited alcohol, tobacco, 
tea, and coffee the day before and during the experiment. In the morning after complete 
emptying of the bladder, a catheter was placed in a forearm vein, subjects were given 400 
ml of water orally and assumed a seated position next to a tank with thermoneutral (34.5 
± 0.2°C) water. After 1 hr the subjects were immersed to their neck into the water bath, 
maintaining the same position for 1 hr. This was followed by another hour of sitting 
outside the tank. Throughout the investigation, 200 ml/hr of water were given orally to 
ensure adequate urine flow. Urine obtained by spontaneous emptying of the bladder was 
collected before (0), after 60 min (60 min), and 60 min subsequent to (120 min) the end 
of W I . Blood samples were obtained at 0, 60 min, and 120 min. ANF was determined in 
extracted plasma samples as described before (4). 
Data are given as mean and standard error. Data were evaluated statistically by paired 
or unpaired Students /-test. 
RESULTS 
Volume stimulation by W I caused a rise of plasma ANF from 6.0 ± 0.6 fmol/ml to 
13.6 ± 2.6 fmol/ml in healthy subjects and from 8.5 ± 1.3 fmol/ml to 16.5 ± 2.6 fmol/ 
ml in cirrhotic patients without ascites; increases were significant at the 0.01 level. In 
cirrhotics with ascites, stimulation of ANF from 7.7 ± 1.3 fmol/ml to 11.4 ± 2.3 fmol/ 
ml was significantly (p < 0.05) blunted as compared to cirrhotics without ascites (Fig. 
1A). 
Renal response to immersion is illustrated in Fig. IB and C. Mean increases in urinary 
volume were found to be 3.64 ± 0.60 ml/min in controls, 2.02 ± 0.81 ml/min in cirrhotics 
without ascites, and only 0.68 ± 0.35 ml/min—not significantly different from baseline 
values—in cirrhotics with ascites. Similar differences were observed in urinary sodium 
excretion: immersion induced a rise by 146 ± 38 (xmol/min in controls, by 75 ± 43 
|xmol/min in cirrhotics without ascites, and by only 43 ± 19 jxmol/min in cirrhotics with 
ascites. Increases in both cirrhotic groups did not reach the level of significance. 
DISCUSSION 
The observation that W I significantly increases ANF plasma levels in a larger number 
of healthy subjects is in accordance with previous results from our laboratory and has 
been confirmed by other investigators (8-11). Similar increases were observed in patients 
420 SECTION IV 
FIG. 1. Plasma levels of atrial 
natriuretic factor (A), urinary vol-
ume (B), and urinary sodium ex-
cretion (C) before (0 min), after 1 
hr (60 min), and 1 hr subsequent 
to (120 min) the end of water im-
mersion in 25 healthy controls, 11 
cirrhotic patients without ascites, 
and 10 cirrhotic patients with as-
cites. O p < 0.05, (**) p < 0.01, 
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with cirrhosis of the liver without ascites. In cirrhotics with ascites, however, stimulation 
of ANF release into plasma was found to be significantly reduced after 1 hr immersion. 
This might be due to a decreased volume stimulus in these patients. However, plasma 
renin activity as an indicator of centrally effective volume decreased in cirrhotics with 
ascites by a ratio not different from that in cirrhotics without ascites or controls (unpublished 
observations). Furthermore, central hemodynamics and intracardiac pressures are influenced 
by W I independent of the degree of ascites (12). Thus, blunted increase of atrial pressure 
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as a stimulus for ANF release does not seem a likely explanation for the observed blunted 
ANF stimulation in these patients. Therefore, a defect of ANF synthesis, release, or metabo-
lism might be suspected in these patients. 
The blunted ANF stimulation is paralleled by reduced increases of urinary sodium excretion 
and urinary volume following immersion in cirrhotics with ascites. Although this might 
suggest a (patho-) physiological role of ANF in volume regulation, no correlations of 
either basal or stimulated ANF with renal response could be found. In view of the involvement 
of several other hormonal systems in volume regulation, however, this finding is not surpris-
ing. 
Furthermore, at comparable baseline plasma levels of ANF, excretion of sodium was 
diminished in cirrhotic patients as compared to controls and in patients with ascites as 
compared to patients without ascites. The renal response to stimulation by water immersion 
was less marked than the increase of ANF in the cirrhotic groups. These findings might 
be consistent with increased activity of sodium retaining principles, counteracting the renal 
action of ANF, or a blunted responsiveness of the kidney to ANF in cirrhosis. 
This study demonstrates a blunted response of ANF release to WI in patients with cirrhosis 
of the liver and ascites and might suggest a role for this novel hormone in impairment of 
acute volume regulation in cirrhosis. 
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